Skip to main content

Table 5 shows relevant metrics for prostate and organs at risk for prescription of 60 and 62 Gy in 20 fractions. Median and interquartile ranges are shown

From: Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients

  Prostate volume PTV Prostate Bladder Rectum
Prescription Dose   D98% D2% D3% D15% D30% D0.01% D5% D22% D38% D57%
60 Gy 40.8
(29.3–46.3)
56.2
(56.2–56.8)
61.4
(61.2–61.9)
58.3
(51.3–58.9)
38.0
(32.1–42.8)
23.2
(19.8–26.5)
59.7
(59.1–60.0)
54.3
(51.6–56.5)
34.1
(30.8–36.3)
15.1
(8.3–18.6)
8.1
(6.8–8.3)
62 Gy 60.0
(38.7–88.7)
58.3
(58.1–58.4)
63.8
(63.5–64.0)
58.1
(54.0–59.0)
33.1
(31.9–37.1)
20.0
(17.0–22.3)
59.9
(59.8–60.1)
50.9
(49.3–55.0)
26.0
(23.5–33.6)
15.6
(13.8–18.9)
9.1
(6.4–10.8)